Certified Advisory Corp’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $850K | Buy |
6,732
+441
| +7% | +$58.1K | 0.07% | 181 |
|
|
2026
Q1 | $877K | Sell |
6,291
-717
| -10% | -$100K | 0.08% | 171 |
|
|
2025
Q4 | $860K | Sell |
7,008
-3,196
| -31% | -$388K | 0.08% | 168 |
|
|
2025
Q3 | $1.13M | Buy |
10,204
+2
| +0% | +$227 | 0.11% | 150 |
|
|
2025
Q2 | $1.13M | Buy |
10,202
+35
| +0.3% | +$3.73K | 0.12% | 143 |
|
|
2025
Q1 | $1.14M | Sell |
10,167
-297
| -3% | -$30.6K | 0.13% | 142 |
|
|
2024
Q4 | $967K | Sell |
10,464
-13
| -0.1% | -$1.17K | 0.1% | 149 |
|
|
2024
Q3 | $878K | Sell |
10,477
-222
| -2% | -$16.9K | 0.1% | 155 |
|
|
2024
Q2 | $734K | Sell |
10,699
-549
| -5% | -$36.6K | 0.09% | 158 |
|
|
2024
Q1 | $824K | Sell |
11,248
-134
| -1% | -$10.3K | 0.12% | 143 |
|
|
2023
Q4 | $922K | Sell |
11,382
-230
| -2% | -$17.9K | 0.14% | 132 |
|
|
2023
Q3 | $870K | Sell |
11,612
-593
| -5% | -$45.6K | 0.16% | 115 |
|
|
2023
Q2 | $941K | Sell |
12,205
-142
| -1% | -$11.3K | 0.17% | 114 |
|
|
2023
Q1 | $1.02M | Buy |
12,347
+9
| +0.1% | +$745 | 0.18% | 118 |
|
|
2022
Q4 | $1.06M | Sell |
12,338
-12
| -0.1% | -$950 | 0.21% | 112 |
|
|
2022
Q3 | $761K | Sell |
12,350
-1,807
| -13% | -$114K | 0.17% | 125 |
|
|
2022
Q2 | $875K | Buy |
14,157
+20
| +0.1% | +$1.24K | 0.2% | 122 |
|
|
2022
Q1 | $840K | Buy |
14,137
+128
| +0.9% | +$8.18K | 0.18% | 123 |
|
|
2021
Q4 | $1.02M | Sell |
14,009
-288
| -2% | -$19.8K | 0.22% | 108 |
|
|
2021
Q3 | $999K | Buy |
14,297
+161
| +1% | +$11.3K | 0.24% | 101 |
|
|
2021
Q2 | $974K | Sell |
14,136
-173
| -1% | -$11.6K | 0.24% | 100 |
|
|
2021
Q1 | $925K | Buy |
+14,309
| New | +$923K | 0.24% | 95 |
|
|
2020
Q2 | $1.14M | Buy |
14,850
+125
| +0.8% | +$9.58K | 0.38% | 62 |
|
|
2020
Q1 | $1.1M | Sell |
14,725
-622
| -4% | -$43K | 0.44% | 56 |
|
|
2019
Q4 | $998K | Sell |
15,347
-1,695
| -10% | -$110K | 0.32% | 78 |
|
|
2019
Q3 | $1.08M | Sell |
17,042
-2,212
| -11% | -$145K | 0.38% | 63 |
|
|
2019
Q2 | $1.3M | Sell |
19,254
-77
| -0.4% | -$5.07K | 0.48% | 50 |
|
|
2019
Q1 | $1.26M | Sell |
19,331
-140
| -0.7% | -$9.3K | 0.53% | 44 |
|
|
2018
Q4 | $1.22M | Sell |
19,471
-1,814
| -9% | -$127K | 0.63% | 35 |
|
|
2018
Q3 | $1.64M | Buy |
21,285
+20
| +0.1% | +$1.51K | 0.76% | 29 |
|
|
2018
Q2 | $1.51M | Sell |
21,265
-996
| -4% | -$70.3K | 0.84% | 27 |
|
|
2018
Q1 | $1.68M | Buy |
22,261
+20,382
| +1,085% | +$1.62M | 0.99% | 24 |
|
|
2017
Q4 | $133K | Buy |
+1,879
| New | +$143K | 0.1% | 145 |
|
Other funds holding GILD
Certified Advisory Corp's GILD Position: Q2 2026 in Review
Certified Advisory Corp increased its Gilead Sciences (GILD) stake by 7% in Q2 2026, buying an estimated $58.1K and bringing the position to 6,732 shares worth $850K. The position accounts for 0.07% of the portfolio, ranked #181.
Certified Advisory Corp first reported a position in GILD in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.68M in Q1 2018. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Certified Advisory Corp held 6,732 shares of Gilead Sciences worth $850K as of Q2 2026.
- Certified Advisory Corp bought 441 Gilead Sciences shares in Q2 2026, an estimated $58.1K.
- Gilead Sciences made up 0.07% of Certified Advisory Corp's portfolio in Q2 2026, its #181 holding.
- Certified Advisory Corp first reported a position in Gilead Sciences in Q4 2017 and has held it in 33 quarters since.
- Certified Advisory Corp's Gilead Sciences position peaked at $1.68M in Q1 2018.
- 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Certified Advisory Corp's 13F filing for Q2 2026, filed 16 Jul 2026.